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Abstract
Respiratory syncytial virus (RSV) infection is a major cause of severe respiratory 
disease in infants and young children worldwide and also forms a serious threat for 
the elderly. Vaccination could significantly relieve the burden of the RSV disease. 
However, unfortunately there is no licensed vaccine available so far. This is partly 
due to disastrous outcome of a clinical trial of formalin-inactivated RSV (FI-RSV) 
in children in 1960s; leading to enhanced respiratory disease upon natural infection. 
These findings contributed significantly to the delay of RSV vaccine development. 
Other key obstacles in development of RSV vaccine such as a peak of severe disease 
at 2–3 months of age, challenging biochemical behavior of key vaccine antigens and 
dependence on animal models that may not truly reflect human disease processes. 
These challenges could be overcome through maternal immunization, structure-
based engineering of vaccine antigens, the design of a novel platform for safe infant 
immunization, and the development of improved animal models. Currently, several 
vaccine candidates are in pre-clinical and clinical trials targeting the diverse age 
groups; young children or older adults from the infection or can reduce incidence, 
mortality and morbidity among the RSV infected individuals.
Keywords: respiratory syncytial virus, vaccines, adaptive immune response, 
adjuvants, animal models, infants, elderly, enhanced respiratory disease,  
innate immune response
1. Introduction
Respiratory syncytial virus (RSV) infection is a major cause of lower respiratory 
tract diseases among infants, young children and immune-compromised individu-
als. RSV infection provides partial immunity and reinfection may occur often 
throughout life. Therefore, RSV infection forms a severe threat in chronically ill 
adults and the elderly [1]. Current studies have demonstrated that RSV also a main 
cause of mortality among the elderly, indeed to similar extents as does influenza 
[2]. Presently, the only approved medication against RSV infection is a prophylactic 
monoclonal antibody, i.e., Palivizumab, which is given as a prophylaxis to high-risk 
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infants [3]. Despite the isolation and characterization of the virus in 1956, efforts 
to develop a safe vaccine have been unsuccessful so far. In a clinical trial conducted 
in young children in the 1960s, a formalin-inactivated RSV (FI-RSV) vaccine did 
not protect against infection rather led to enhanced respiratory disease (ERD) upon 
subsequent exposure of the vaccinees to the natural virus. These findings that inac-
tivated RSV vaccines may prime for ERD has contributed significantly to the delay 
of vaccine development. Other major challenges for development of RSV vaccine 
are a disease severity at 2–3 months of age, challenging biochemical behavior of 
key vaccine antigens and dependence on animal models that may not exactly mimic 
human disease processes. These challenges could be overcome through maternal 
immunization, structure-based engineering of vaccine antigens, the design of a 
novel strategy for safe immunization of infants, and the development of better 
animal models (Table 1).
2. Respiratory syncytial virus
RSV is an enveloped non-segmented negative-sense single-stranded (ss) RNA 
virus belonging to the Orthopneumovirus genus and Pneumoviridae family [4]. Two 
serotypes of RSV have been recognized i.e., RSV A and RSV B [4].
The RSV genome comprises 10 genes of 15.2 kb nucleotides encodes 11 proteins 
[5]. RSV comprises of a nucleocapsid enclosed by a lipid envelope with a diameter 
of 150–300 nm (Figure 1: RSV particle and RSV-genome). RSV expresses two 
non-structural proteins such as NS1 and NS2. These are detected only in RSV-
infected cells and are not packaged into the virion. They mainly serve to inhibit type 
I interferon responses [7]. Eight RSV proteins are present in the virion particles. 
Among these structural proteins, three are membrane proteins: the attachment 
protein G, the fusion protein F and the small hydrophobic protein (SH). The heavily 
Target 
groups
Considerations Vaccines approaches
Infants (<6 
months)
Goal: Prevent severe complications
Challenges: Less developed immune system; 
more susceptible to disease; FI-RSV enhanced 
respiratory disease history, maternal Abs present
1. Live-attenuated vaccines
2. Gene based vectors
3. Virus chimeric vectors
Children 
(6–24 
months old)
Goal: Prevent severe complications
Challenges: To achieve the clinical end point is 
not easy; FI-RSV enhanced respiratory disease 
history
4. Gene based vectors
5. Live-attenuated vaccines
6. Virus chimeric vectors
Elderly 
people (>65 
years)
Goal: Po provide protection from infections and 
complications
Challenges: Lot of previous infections can 
decrease response to vaccine; necessary to boost 
up protection provided by natural infection; 
absence of indicators for severity of disease, 
diagnosis difficult
7. Subunit proteins having 
adjuvant
8. Gene based vectors having 
subunit proteins
9. Vaccines including virus like 
particles with adjuvants
Pregnant 
women
Goal: To prevent transmission from mother to 
infants, maximize the protection of infants
Challenges: Lot of previous infections can 
decrease response to vaccine, necessary to boost 
up the antibody level for protection of infants
10. Subunit proteins in combina-
tion with standard adjuvants
11. Vaccines having virus like 
particles with adjuvants
Table 1. 
Key target groups for vaccine candidates.
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glycosylated G protein is responsible for viral attachment to the cell. The F protein 
not only contributes to binding of the virus to cells, but also plays a crucial part dur-
ing entry of virus by mediating fusion of the viral envelope with the cell membrane, 
thereby allowing deposition of the viral genome into the cytosol [8]. Besides this, F 
protein is a mediator of syncytium formation [5]. The function of the SH protein, 
which is mostly found in the infected-cell membrane, is unknown [9]. Other viral 
structural proteins are the nucleocapsid protein (N), the matrix protein (M), the 
phosphoprotein (P), the RNA-dependent RNA polymerase (L) and the M2 gene 
product M2-1: all these proteins are located inside the viral particle. Whereas the 
M2-2 gene product is packaged in the virion is currently unknown [10]. The function 
of the matrix (M) protein is to connect the viral nucleocapsid with the lipid envelops 
and it is also responsible for viral particle assembly. The M2-2 protein is involved in 
regulation of viral transcription [11]. M2-1 functions as transcription-elongation 
factor [12]. The phosphoprotein (P) and nucleocapsid protein (N) are essential for 
transcriptional activity, while the L protein has RNA polymerase activity.
3. Epidemiology
RSV infections have a distribution worldwide. These infections are more com-
mon during the winter season in temperate climates. However, RSV infections may 
occur throughout the year in tropical climates, but can be more frequent in the 
Figure 1. 
Schematic representation of the RSV virion and its genome composition (adapted and modified with 
permission from [6]).
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monsoon season in some areas [13–15]. Although infection can be established in 
several laboratory animals, however, natural infection with RSV appears to be lim-
ited to apes and humans [16]. RSV transmission occurs via direct contact or con-
tact with contaminated surfaces that harbor respiratory secretions. The virus can 
survive for many hours on toys or other substances, which explains the high rate of 
nosocomial RSV infections particularly in pediatric wards. The incubation period 
for RSV infection ranges between 2 and 7 days [17]. Almost 70% of newborns are 
infected in the first year of their life. By the age of 2 years, almost all children have 
been infected and over 50% will have been infected twice [18]. RSV infections are 
common in the population and re-infections probably occur frequently. In a study 
conducted by Hall et al., 1991, almost 25% of adult volunteers could be re-infected 
with RSV of the same group, 2 months after a natural infection [19].
RSV infection is the major source of severe respiratory illness in infants and 
young children and is the most frequent cause of hospitalization of infants and 
young children in industrialized countries [20]. RSV infections differ in disease 
severity, from a mild cold to bronchiolitis or pneumonia. Almost 3% of infants 
infected with RSV need hospitalization due to respiratory failure and feeding 
problems [21]. Among the hospitalized infants, 20% need mechanical ventilation 
[22]. The highest morbidity of RSV disease is seen in children under the age of 
6 months [23] and in children with associated risk factors such as prematurity, 
broncho-pulmonary dysplasia, congenital heart disease with increased pulmonary 
circulation or immune deficiency [24–27]. According to WHO estimates, RSV 
disease burden is ~64 million cases and 160,000 deaths per year worldwide. In USA, 
about 85,000–144,000 infants are admitted to hospitals with RSV infection annu-
ally which corresponds to 20–25% of pneumonia cases and about 70% bronchiolitis 
cases in the hospital [28, 29]. The elderly people are also at risk for extreme RSV 
disease and almost 14,000–62,000 RSV-associated hospitalizations of the elderly 
occur in USA with an approximate annual cost of RSV pneumonia-related hospital-
izations of $150–680 million [30, 31].
4. Pathogenesis
After RSV infection, virus primarily multiplies in the epithelial cells of the naso-
pharynx [32]. The exact mechanism by which RSV spreads to the lower respiratory 
tract is not clear yet. Currently, it is not known why the disease progression is mild 
in most children, but severe in a small subgroup. Different studies have described 
associations between disease severity and genes involved in allergic responses, like 
IL-4 and IL-4 receptor genes, and genes for inflammatory cytokines, e.g., IL-6 
and IL-8 [33]. Furthermore, up-regulation of chemokines during RSV infection is 
associated with disease severity. For example, CCL11 (eotaxin), RANTES (CCL5) 
and MIP1α have been found in higher levels in cases with more severe RSV infection 
and ERD [34, 35].
Several other factors could be associated with disease severity, for example, 
environmental factors, patient intrinsic factors, virus strain and viral load. 
Environmental factors like a high number of siblings, attendance of day-care centers 
and socio-economic status can enhance the chance of early exposure and may 
increase the risk of developing lower respiratory tract disease [36]. Other factors like 
geographical area, parental smoking and the use of wood-burning stoves have also 
been linked to an enhanced risk of severe RSV infections [37–40]. Patient-intrinsic 
factors like a compromised respiratory function, e.g., bronchopulmonary dysplasia 
(BPD) [25], or congenital heart disease with increased pulmonary circulation may 
significantly enhance the risk to develop severe RSV infection [41]. It is reported 
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in some studies that RSV-strain A is responsible for more severe disease [42], 
while other studies report no difference between RSV A and B strains [43, 44]. 
Furthermore, the course of lower respiratory disease was found to be associated with 
a high viral load [45]. Finally, RSV-specific immunity induced by vaccination may 
also be involved in immunopathological mechanisms leading to enhanced disease. 
This hypothesis is mainly based on experimental animal data [46], and on observa-
tions from a clinical trial where, as indicated above, infants were vaccinated with 
FI-RSV vaccine, which resulted in enhanced respiratory disease (ERD) upon natural 
infection [47–49]. The notion that inactivated-RSV preparations can prime for ERD 
is one of the factors that has delayed the development of an effective RSV vaccine.
5. Therapeutic approaches against RSV
Only supportive treatment is available. In supportive treatment we can use 
corticosteroids, bronchodilator and oxygen supplement. These are effective to some 
extent [50]. It is viral infection, so the use of antibiotics is not recommended, but 
according to some studies antibiotics can be used to some extent but not regularly 
to prevent the secondary bacterial infection such as urinary tract infections [51]. 
Corticosteroids also cannot be used routinely because they are the immunosup-
pressors [52]. The only recommended antiviral RSV treatment at clinical level is 
ribavirin. Studies are present which indicate the conflicting results of ribavirin use. 
It is also less effective and very costly. Due to the conflicting results of ribavirin, 
American Academy of Science recommendation is that ribavirin should not be 
routinely used in children having the symptoms of bronchiolitis [53]. Ribavirin 
completes its function by preventing the polymerase of virus. So ribavirin can 
inhibit both the DNA and RNA viruses. Ribavirin action may result in anemia 
and other adverse reactions such as hypersensitivity. According to few studies, 
ophthalmologic disorders also have been noted after the use of ribavirin. All these 
side-effects lead towards the limited use of ribavirin in RSV treatment [54]. A study 
indicated that ribavirin might be used in target groups such as children having RSV 
infection with comorbid immunosuppression, but it is necessary to investigate and 
verify more data about its recommendation [55, 56]. It has also been noted that 
once the disease has occurred, no effective treatment is available for preventing the 
disease. Another study explained its failure in treatment describing that inhibiting 
the replication of virus alone is not enough to block the virus mediated pathogenesis 
in host. So, due to limited treatment options and high disease burden, it is necessary 
to discover the new treatment as well as prophylactic policies.
Now there is focus on F protein for the development of anti-RSV drugs as well 
as vaccines. Researches are being conducted for the development of numerous 
antiviral drugs and antibodies that are in preclinical development stage. Some of 
the new vaccine and drugs are in evaluation stage. Experiments were conducted on 
cotton rats and mice in which RSV F specific nano-bodies and immunoglobulin were 
administered by intranasal route. This led to reduction in lung inflammation and also 
decreased the virus replication after RSV infection [57]. The RSV G protein is also 
being targeted for the development of drugs, prophylactic agents and vaccines. The 
RSV G protein consists of CX3C motif and is homologous in structure with CX3CL1 
[58]. RSV G protein increases the infection rate by binding the receptor CX3CR1. 
Experiments have shown that anti- RSV G monoclonal antibodies have the ability 
to block the interaction between RSV G CX3C-CX3CR1. This interaction inhibition 
decreased the lung inflammation. Experiments conducted on rats also have been 
shown that RSV G monoclonal antibodies have the greater ability to decrease the pul-
monary inflammation when compared with anti-F monoclonal antibodies [59–61].
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6. Current status of RSV vaccine
At present, there is no approved vaccine is present in the market which can 
protect from RSV infection. Due to increased burden of disease, it is essential to 
develop a vaccine that can give protection against the disease [47]. Recently, a lot of 
RSV vaccine candidates have been emerged using a variety of advanced technolo-
gies. About 60 RSV vaccines candidates targeting the pediatric and older popula-
tions are in development stage and some are also in preclinical stage [62]. According 
to a study, 16 RSV vaccine candidates are in clinical development stage [62].
6.1 Live attenuated vaccine
During 1960s, after the failure of formalin inactivated RSV vaccine (FI-RSV), 
struggles were started to develop live-attenuated vaccines candidates. By serial 
passaging of RSV A2 strain at lower temperature, live attenuated vaccines were 
produced; however, it was hard to achieve the balance between immunogenicity 
and safety [62].
Today, a lot of the cold passage (cp) and temperature sensitive (ts) vaccines have 
been produced. Evaluation of one cpts-248/404 was done in 1–2 month old aged 
infants. But it led to the problem such as congestion of upper respiratory tract and 
so, it was not followed for more investigations. After this struggles were done to 
attenuate the cpts-248/404 strain and many mutants were produced. After evalua-
tion these generated mutants were found to be over or under attenuated [63].
There is another live-attenuated type RSV vaccine which includes M-2 gene 
deletion is being tested on nonhuman primates. The M-2 gene regulates the transi-
tion from transcription to RNA replication. Studies have shown that by the dele-
tion of M-2 gene, viral RNA replication is decreased but at the same time G and 
F protein expression is increased through transcription which means that virus is 
attenuated at adequate level and may lead to neutralizing antibody response [64].
NS2 is another target gene for producing live attenuated vaccine RSV NS2. 
gene increases the shedding of epithelial cells and reduces or inhibits the antiviral 
cellular type 1 IFN induction and IFN response of the host. Vaccines which include 
the deletion of NS2 gene are stable genetically and sensitive to temperature to some 
extent [65, 66]. SH gene also has been considered for deletion for the live attenu-
ated vaccines. It is believed that SH gene is involved in viral fusion. According to 
few studies, it is involved in the inhibition of apoptosis by blocking the TNF- alpha 
pathway. To obtain the sufficient attenuation level to get the safety is the major 
continuing problem for live attenuated RSV vaccine [65–67].
6.2 Subunit vaccines
RSV G and F glycoproteins lead to the induction of neutralizing antibodies. 
These have been evaluated as potential vaccine candidate [68]. Subunit vaccines 
have the potential to be used for maternal immunization. They are also useful candi-
dates for elderly immunization. A number of subunit vaccines have been evaluated 
recently. The vaccines which are in clinical trials are co-purified G, F and M pro-
teins; purified F glycoprotein (PFP-1, PFP-2 and PFP-3); and BBG2NA etc. [69–76].
RSV PFP-1, PFP-2 and PFP-3 are the candidates which have been evaluated in 
children of >12 months of age and also in elderly target populations. These vaccine 
candidates consist of purified glycoprotein which are adsorbed to Al(OH)3 (PFP-1 
and PFP-2) or AlPO4 (PFP-3). These candidates were sufficiently tolerated by the 
target populations but acute reactions were also observed up-to minimum level. 
There was no observation of enhanced disease occurrence [70–77].
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7. Challenges to RSV vaccine development
7.1 Early age when immature immune system of neonates
The most noteworthy risk group for extreme RSV infection is infants under a 
half year of age [78, 79]. Practically speaking, first dose should be administered at 
the age of 2 months. Full term newborn children obtain maternal antibodies during 
the latter 50% of gestation and levels of antibody remain moderately high for a half 
year after the birth [80]. This would interfere when RSV vaccine would be done 
[81]. So there is need of an ideal vaccine which will not interfere with the maternal 
antibodies and will give protection in the presence of maternal antibodies. A few 
investigations show that newborn children under the age of 8 months have a less 
serum counter acting agent (antibody) response to characteristic RSV disease as 
compared to elder ones [82]. A less developed immune system may be the reason 
of this reduced immunity level, but maternal antibodies may also suppress the 
immune response [83].
Recent schedule for hepatitis B, diphtheria, rotavirus, pneumococcus, pertus-
sis, tetanus, Haemophilus influenzae type b and poliovirus show that vaccine for 
these infectious diseases will be done ideally after birth at 2, 4 and 6 months of 
age. Vaccination for RSV should be ideally administered at 6 months of age, so it 
is necessary and important to make sure that RSV vaccine should not interfere the 
working and efficacy of other routinely used vaccines during the childhood [84].
7.2 Induction of low affinity neutralizing antibodies
RSV vaccine was developed shortly after it was isolated. In 1960, FI-RSV 
vaccine was injected by intramuscular route in 2–7 months old infants and 
children. Instead of providing protection against wild type RSV infection, 
FI-RSV enhanced the respiratory disease development following wild type RSV 
infection during the subsequent RSV season. Lungs of children and infants with 
enhanced diseased were rich with large numbers of eosinophils and this was 
not found in patients of natural infection with RSV. After this disastrous out-
come, there was need to develop a safe RSV vaccine including the evaluation of 
enhanced disease [47–49, 85, 86].
These different immunopathology aspects which were seen in humans after 
FI-RSV vaccine and enhanced disease were later studied in non-human primates. 
In newborn macaques which were FI-RSV vaccinated and then infected with RSV 
virus, enhanced disease with increased level of eosinophils and neutrophils were 
seen [87–91]. FI-RSV produced the increased level of ELISA titer RSV antibody 
because it was highly immunogenic, but the provoked antibodies were non-neu-
tralizing. Antibodies produced did not provide the protection against virus because 
it could not prevent the fusion of virus [92, 93]. FI-RSV induced resulted RSV 
antibodies were also known to be of decreased avidity and this may be the result of 
having lack of maturation [94–97].
7.3 Lack of appropriate animal models
No ideal animal model for RSV vaccine is present which can be used for its 
evaluation. African green monkey kidney cells (Vero cells) were used for produc-
tion of RSV. High titers of RSV were observed on Vero cell line. Similar results were 
obtained when grown on human cells (HEp-2). On both these cell lines, RSV infec-
tion led to syncytia formation. These cell lines were used extensively to characterize 
the live attenuated RSV vaccines. In recent studies, there are reports that NHBE 
The Burden of Respiratory Syncytial Virus Infection in the Young
8
(normal human bronchial epithelial) and HAE (human airway epithelial) cells are 
used to create model human nasopharyngeal mucosa. RSV infection did not show 
any pathological sign and also not led to syncytia formation on NHBE and HAE cell 
lines [98, 99].
Experiments to study attenuation of live attenuated RSV vaccine were also 
conducted on BALB/c mice, found permissive to infection to some extent. 
Advantages for mouse studies are that reagents are readily available which can 
be used for measurement of infection immune correlates [99–104]. Several non-
human primates act as host for RSV. RSV can replicate in the nasopharyngeal tract 
of their host. Macaques, African green monkeys, Chimpanzees and bonnet mon-
keys have been used to model RSV infection [105–112]. Relative viral titers of live 
attenuated RSV vaccines compared to wild type RSV disease can also be measured. 
Chimpanzees are the only non-human hosts which develop and show the clinical 
sign and symptoms of coryza following RSV infection. They are much permissive 
to RSV infection. So they are used for evaluation of comparative level of attenua-
tion among vaccines which are candidates in humans. But it has been shown by the 
recent studies that chimpanzee is not completely predictive of attenuation in young 
newborns. They are also scare and expensive. Study conducted by Karron et al. 
showed that those RSV vaccines sensitive to temperature and also had high degree 
attenuation in chimpanzee, were able to produce infection in lower respiratory tract 
in children [112].
7.4 Absence of RSV disease liability data and commercial risk
It is known that those children and persons primed with RSV are not at risk to 
RSV enhanced illness, but the absence of enhanced disease illness in RSV primed 
persons does not support the prediction that it will not be present in RSV naïve 
population. So it is very difficult to build up safety data which can support and be 
used for testation of novel RSV vaccine in newborns having age <6 month which is 
primary target population [113, 114]. There is absence of information (data) on RSV 
related mortality. This has prevented exact appraisal of the expenses and advan-
tages of RSV vaccines and prioritization of vaccines for various target populaces 
[49]. Lack of information on disease liability data is a big problem in less developed 
countries where mortality cases are concentrated [115].
7.5 Limited resources
Clinical investigations of applicant vaccines in the target populace are funda-
mental to figure out which vaccines ought to be created for licensure, yet these 
examinations are tedious and costly, what’s more, assets for these investigations are 
restricted. Measurement of impact of vaccine on disease in all target populations is 
very difficult and problematic. It is easy to diagnose RSV infection in infants and 
children because their respiratory secretions have high titers of RSV and so are easy 
to detect. Titers of virus in adults are low and sensitive RT-PCR assay is used for 
detection purpose. If there is a decrease in severity of disease, it is a good indication 
of vaccine being effective. Measures done for disease severity are not accurate at 
all ages of target populations. So there is need that larger and most costly studies 
should be performed [116].
7.6 Emerging RSV variants/mutation in RSV genome
RSV is divided antigenically into two groups which are RSV-A and RSV-B.  
These groups are further divided into genotypes as well as variants. It has been 
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investigated that different viruses belong to these different groups; genotypes as 
well as variants co-circulate in epidemics. So it is very difficult to develop an effec-
tive vaccine due to the presence of virus antigenic diversity as well as variability. 
Like other RNA viruses, RSV has high nucleotide substitution rate (10−3–10−4). 
Spontaneous type of deletions of G and SH genes have been studied in vitro. RSV 
genome encodes 11 proteins; one of them is G protein which is most variable having 
2 hypervariable regions. G protein has been investigated to accumulate amino acid 
changes periodically. RSV genotypes having the amino acids duplications in G 
proteins also have been isolated.
7.7 Disruption of antigenic epitopes
Researches had shown that formalin inactivation caused the alterations in 
the epitopes of the G and F proteins and as a result non-neutralizing antibodies 
were developed which led to formation of immune complex in the lungs [57, 69]. 
Recent studies have shown that changes in the properties of F protein occur during 
interaction of virus and host cell. The pre fusion (pre-F) which is highly energetic, 
transitions irreversibly into post fusion (post-F) form which is low energetic and 
stable, this occurs during insertion process of virus into host cell membrane. By this 
process, fusion of virus to host occurs. Although pre and post F are not structur-
ally similar, they share 2 antigenic regions. Neutralizing antibodies target these 
antigenic regions. Pre F also has 3 other antigenic sites not present in post-F. These 
sites are neutralization sensitive [68–72]. It is investigated that pre-F conformation 
changes to post-F conformation during the mechanism of formalin as well as heat 
inactivation and this change is irreversible. As a result of this change, complete 
loss of epitopes occurs. So this process explains the one of the reasons for failure of 
FI-RSV [69, 71].
7.8 Older age when immune-senescence of the elderly people
Elder target population group possess a considerable disease burden. The elder 
group has preexisting immunity, which makes it inconvenient to increase the 
existing immunity. Furthermore immune-senescence may lead to decrease in the 
efficacy of vaccine [116]. Immune-senescence is a challenge for proper vaccination 
in older target populations. RSV disease burden increases in elderly people in pres-
ence of underlying diseases such as cardiac and pulmonary conditions. Live attenu-
ated vaccines are found not to be immunogenic in elderly people. So now focus is on 
subunit vaccines for this target group [115, 117].
8. Future horizons in RSV vaccine and RSV therapeutics
• Continuous struggles are going on for the development of effective and 
safe RSV vaccines for each target group (infants, children, elders including 
pregnant women). Previous struggles made to build up a safe vaccine were 
failed. High antibody production was seen by the use of FI-RSV vaccine in 
1960. However, unfortunately vaccinated children developed a severe disease 
after administration of FI-RSV vaccine. Difficulties and barriers associated 
with vaccine development particularly live attenuated vaccine are enhanced 
respiratory disease, maternal antibodies, nasal congestion, low immunogenic-
ity, genetic variability and instability, immature immune system of infants, 
vaccine virus transmission and immune-senescence as well as preexisting 
immunity in elders. However, these problems are being slowly overcome [118].
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• Major achievements in last 3 years are that nanoparticle based vaccines and live 
vector vaccines have been investigated in different phase 1 and phase 2 trials 
and efficient results obtained. These vaccines step forward into later phase 
trials for evaluation [119]. So, there is hope that safe and well tolerated vaccine 
candidates will provide a long lasting immunity to all target groups, may be in 
our hands with in ~5–10 years.
• In vitro tissue culture system has been developed, that are being used for 
predicting the efficacy and safety of candidate vaccines.
• Palivizumab is only the success which is available to clinicians and is being 
used to reduce the burden of RSV. Palivizumab has decreased hospitalization; 
however, its use is limited due to high cost. There is hope that this approved 
prophylactic approach will be available to everyone and may soon come into 
extensive and widespread use. Palivizumab is patent of MedImmune and this 
patent is near to expire. So with expiry of this patent, there is hope that a cost 
effective palivizumab version will be developed. A recent technology hub has 
been established by the World Health Organization (WHO), the purpose of 
this is to increase the production of biosimilar versions [120]. There is hope 
that these products will be available in the market at low and affordable cost. 
These good initiatives will greatly reduce the mortality rates caused by RSV in 
developing world.
• Oral antivirals such as GS-5806 and a nucleoside analogue ALS-008176 have 
been passed through trials and they significantly decreased the replication 
of virus in human controlled experiments [121]. Nanobodies (single domain 
antibodies) has also been developed that protected the mice from infection and 
now are ready for clinical development. These results renewed the hope that an 
effective antiviral treatment for different risk populace will be on the horizon 
in next few years [57].
9. Conclusions
One of the most common causes of the respiratory tract diseases is the RSV 
affecting infants, young children and the elderly people. Only supportive treat-
ment is available such as corticosteroids, bronchodilators, oxygen supplement and 
ribavirin etc. which may not be occasionally effective. Palivizumab has decreased 
hospitalization; however, its use is limited due to high cost. Despite it is the era 
of progress and technology, no RSV licensed vaccine is available in the market to 
prevent RSV infection. Natural infection also provides partial immunity. A suc-
cessful vaccine candidate will provide the long term protective immunity and must 
not lead to induction of enhanced RSV disease. For RSV vaccine development 
different target groups are being considered such as elders including pregnant 
women, children and infants. Each of these target groups has different challenges 
for vaccine development. Maternal antibodies, enhanced disease and immature 
immune system are the major barriers for vaccine development in the infants. The 
children >6 months of age have more mature immune system than infants but still 
can be at the risk of enhanced disease from non-live RSV vaccine. For elderly target 
population immune-senescence as well as pre-existing immunity is the barrier for 
vaccine development.
An ideal RSV vaccine should be safe, well tolerated and provide long last-
ing immunity as compared to natural infection against both RSV strains A and 
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B. Further, it is recommended that separate vaccines should be developed for each 
target group. The tools that ought to enable us to build up a sheltered and successful 
RSV vaccine are accessible and our challenge is to utilize them wisely. We trust the 
suggestions for vaccine advancement noted above can support researchers, subsi-
dizing offices, and industry center their endeavors and assets most productively 
and viably.
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